These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 2904648

  • 1. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
    de Yebenes JG, Fahn S, Lovelle S, Jackson-Lewis V, Jorge P, Mena MA, Reiriz J, Bustos JC, Magariños C, Martinez A.
    Mov Disord; 1987; 2(3):143-58. PubMed ID: 2904648
    [Abstract] [Full Text] [Related]

  • 2. The effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency.
    de Yebenes JG, Fahn S, Jackson-Lewis V, Mena MA.
    Mov Disord; 1987; 2(4):291-9. PubMed ID: 2904650
    [Abstract] [Full Text] [Related]

  • 3. Intracerebroventricular infusion of dopamine and its agonists in rodents and primates. An experimental approach to the treatment of Parkinson's disease.
    Garcia de Yebenes J, Fahn S, Mena MA, Pardo B, Casarejos MJ.
    ASAIO Trans; 1988; 34(4):951-7. PubMed ID: 2905893
    [Abstract] [Full Text] [Related]

  • 4. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
    de Yebenes JG, Fahn S, Jackson-Lewis V, Jorge P, Mena MA, Reiriz J.
    J Neural Transm Suppl; 1988; 27():141-60. PubMed ID: 3165432
    [Abstract] [Full Text] [Related]

  • 5. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P, Marsden CD.
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [Abstract] [Full Text] [Related]

  • 6. Intracerebroventricular infusion of (+)-4-propyl-9-hydroxy-naphthoxacine in monkeys with MPTP-induced akinesia.
    de Yébenes JG, Fahn S, Goodman R, Jamrosik Z, Pezzoli G, Popalski S.
    Adv Neurol; 1990; 53():231-8. PubMed ID: 1978516
    [No Abstract] [Full Text] [Related]

  • 7. PHNO, a novel dopamine agonist, in animal models of parkinsonism.
    Koller W, Herbster G, Gordon J.
    Mov Disord; 1987; 2(3):193-9. PubMed ID: 2904649
    [Abstract] [Full Text] [Related]

  • 8. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism.
    Senthilkumar KS, Saravanan KS, Chandra G, Sindhu KM, Jayakrishnan A, Mohanakumar KP.
    Behav Brain Res; 2007 Nov 22; 184(1):11-8. PubMed ID: 17765334
    [Abstract] [Full Text] [Related]

  • 9. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain.
    Asanuma M, Ogawa N, Nishibayashi S, Kawai M, Kondo Y, Iwata E.
    Arch Int Pharmacodyn Ther; 1995 Nov 22; 329(2):221-30. PubMed ID: 8540762
    [Abstract] [Full Text] [Related]

  • 10. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J.
    Wien Med Wochenschr Suppl; 1986 Nov 22; 98():1-18. PubMed ID: 3097965
    [Abstract] [Full Text] [Related]

  • 11. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun 22; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB, Murrin LC, Pfeiffer RF, Deupree JD.
    Clin Neuropharmacol; 1984 Jun 22; 7(3):247-57. PubMed ID: 6435870
    [Abstract] [Full Text] [Related]

  • 15. Dopamine stimulation via infusion in the lateral ventricle.
    Biagioni F, Busceti CL, Molinaro G, Battaglia G, Giorgi FS, Ruggieri S, Fornai F.
    Ann N Y Acad Sci; 2006 Aug 22; 1074():337-43. PubMed ID: 17105930
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
    Murer MG, Dziewczapolski G, Menalled LB, García MC, Agid Y, Gershanik O, Raisman-Vozari R.
    Ann Neurol; 1998 May 22; 43(5):561-75. PubMed ID: 9585350
    [Abstract] [Full Text] [Related]

  • 18. The influence of acute and chronic administration of 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline on the function of the nigrostriatal dopaminergic system in rats.
    Lorenc-Koci E, Antkiewicz-Michaluk L, Kamińska A, Lenda T, Zieba B, Wierońska J, Smiałowska M, Schulze G, Rommelspacher H.
    Neuroscience; 2008 Oct 28; 156(4):973-86. PubMed ID: 18809471
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP, Rüther E.
    Nervenarzt; 1985 Feb 28; 56(2):69-81. PubMed ID: 3982566
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.